Bristol-Myers Squibb Company BDR (BMYB34)

390.00
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    180.00/0.00
  • Day's Range:
    390.00 - 390.00

BMYB34 Overview

Prev. Close
380
Day's Range
390-390
Revenue
11.7B
Open
390
52 wk Range
302.02-418.5
EPS
3.04
Volume
0
Market Cap
821.96B
Dividend (Yield)
7.4077
(1.90%)
Average Volume (3m)
874
P/E Ratio
23.23
Beta
0.423
1-Year Change
17.31%
Shares Outstanding
2,135,255,158
Next Earnings Date
-
What is your sentiment on Bristol Myers Squibb Company BDR?
or
Market is currently closed. Voting is open during market hours.

Bristol-Myers Squibb Company BDR News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Bristol-Myers Squibb Company BDR Company Profile

Bristol-Myers Squibb Company BDR Company Profile

Employees
30250
Market
Brazil
  • Type:Equity
  • Market:Brazil
  • ISIN:BRBMYBBDR000

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyStrong BuyStrong Buy
Technical IndicatorsNeutralNeutralStrong BuyStrong BuyStrong Buy
SummaryNeutralNeutralStrong BuyStrong BuyStrong Buy